Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: Subanalysis of the EMPA-REG OUTCOME randomised trial
Diabetologia - Clinical and Experimental Diabetes and Metabolism | Jul 11, 2018
Most read this week